Transactions
2
Insider / Immunovant, Inc.
Geffner Michael
Chief Medical Officer at Immunovant, Inc.
- Company
- Immunovant, Inc.
- Ticker
- IMVT
- First filing on record
- October 10, 2025
- Latest trade on record
- October 22, 2025
- SEC filings
- EDGAR ↗
Geffner Michael, Chief Medical Officer at Immunovant, Inc., has disclosed 2 transactions in IMVT since October 10, 2025: 0 purchases (0 open-market buys) and 2 sales, worth about $70K at the reported prices. The latest was filed October 24, 2025, 2 days after the trade.
Open-market buys
0
Sales
2
Avg. disclosure lag
2.0d
Trading in charts
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Geffner Michael has traded 1 stock on record; the largest by dollars is IMVT.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 2 | 3,867 | $70K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2025 | 2 | 0 | 2 · $70K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| IMVT | Sell S | October 22, 2025 | October 24, 2025 | 2d | 2,595 | $19 | $49K | Form 4 ↗ | ||
| IMVT | Sell S | October 8, 2025 | October 10, 2025 | 2d | 1,272 | $16 | $21K | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 24, 2025 | Form 4 | 0001764013-25-000144 | 1 | published | EDGAR ↗ |
| October 10, 2025 | Form 4 | 0001764013-25-000140 | 1 | published | EDGAR ↗ |
Other insiders at Immunovant, Inc.
- Venker Eric President & Immunovant CEO 96 rows
- Stout Jay S Chief Technology Officer 20 rows
- Gloria Melanie Chief Operating Officer 17 rows
- Pande Atul Director 17 rows
- Torti Frank President and Vant Chair 17 rows
- Van Tuyl Christopher Chief Legal Officer 15 rows
- Fromkin Andrew J. Director 14 rows
- Girao Tiago Chief Financial Officer 7 rows
- Hughes Douglas J. Director 4 rows
- Bauer Jake Director 3 rows
Everyone on file, with contracts and lobbying under the company's name: Immunovant, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 2 | October 10, 2025 | October 24, 2025 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.